Trial Comparing the Safety of Two Different Intravenous Iron Formulations
Status:
Suspended
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the safety profile using equal doses of intravenous
iron dextran versus iron sucrose. The researchers hypothesize that significantly more
patients receiving intravenous iron dextran (using the current intermediate molecular weight
product) will have severe adverse outcomes than patients receiving iron sucrose in the adult
non-hemodialysis outpatient population. Secondly, since these severe reactions may require
additional nursing time and physician interventions that may negate any cost advantage of
iron dextran, the researchers hypothesize that iron sucrose will be more cost-effective than
iron dextran.
Phase:
Phase 4
Details
Lead Sponsor:
London Health Sciences Centre
Treatments:
Dextrans Ferric Compounds Ferric Oxide, Saccharated Iron Iron-Dextran Complex